Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.

ABSTRACT:

Introduction

Renal medullary carcinoma (RMC) is a rare and lethal renal cell carcinoma characterized by the loss of tumor suppressor SMARCB1. Molecular profiling studies have suggested that RMC cells may be vulnerable to therapies that generate DNA damage, such as the combination of the nucleoside analog gemcitabine, and topoisomerase inhibitor doxorubicin.

Patients and methods

We retrospectively analyzed the records of patients with RMC treated with gemcitabine plus doxorubicin at our institution between January 2005 and September 2020. Best radiographic response and disease progression (RECIST v1.1) were assessed by a blinded radiologist.

Results

Sixteen patients were included in the study. All but 1 patient (93.8%) received prior platinum-based chemotherapy. Gemcit

SUBMITTER: Wilson NR 

PROVIDER: S-EPMC12289336 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature